Isofol Medical ABOSTO:ISOFOL -0.42%30 Quick Ratio is 5.57 as of Mar. 2026, which is 4% below its 10-year median of 5.81. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Isofol Medical AB ranks better than 62.89% on this metric.
Isofol Medical AB has a quick ratio of 5.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for Isofol Medical AB's Quick Ratio or its related term are showing as below:
OSTO:ISOFOL'
s Quick Ratio Range Over the Past 10 Years
Min: 1.21 Med: 5.81 Max: 42.87
Current: 5.57
During the past 11 years, Isofol Medical AB's highest Quick Ratio was 42.87. The lowest was 1.21. And the median was 5.81.
OSTO:ISOFOL's Quick Ratio is ranked better than 62.89% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs OSTO:ISOFOL: 5.57
Isofol Medical AB (OSTO:ISOFOL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Isofol Medical AB Quick Ratio Related Terms
Isofol Medical AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Isofol Medical AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ISOFOL vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Isofol Medical AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Isofol Medical AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Isofol Medical AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Isofol Medical AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Isofol Medical AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Isofol Medical AB (OSTO:ISOFOL) has a Quick Ratio of 5.57 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Isofol Medical AB and its competitors. This is near median its historical median of 5.81. Over the past decade, Isofol Medical AB's Quick Ratio has ranged from 1.21 to 42.87. According to the industry distribution chart, Isofol Medical AB ranks #524 out of 1412 companies in the Biotechnology industry, placing it in the top 37.1%.
Is Isofol Medical AB's Quick Ratio too high?
Isofol Medical AB's current Quick Ratio of 5.57 is near median its 10-year median of 5.81. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 42.87. The Biotechnology industry median Quick Ratio is 3.60. Isofol Medical AB's value of 5.57 is 54.7% above this industry median. Based on the distribution chart, Isofol Medical AB ranks #524 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Isofol Medical AB ranks #524 out of 1412 companies for Quick Ratio. This puts Isofol Medical AB in the upper half of its industry. The industry median Quick Ratio is 3.60. Isofol Medical AB's value of 5.57 is 54.7% above this benchmark. Historically, Isofol Medical AB's own Quick Ratio has ranged from 1.21 to 42.87 over the past decade. While the company's 10-year median is 5.81 vs. the industry median of 3.60, Isofol Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Isofol Medical AB's current Quick Ratio of 5.57 is 54.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Isofol Medical AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Isofol Medical AB's current Quick Ratio is 5.57, which is near median its own 10-year median of 5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Quick Ratio of 5.57. The current Quick Ratio is 5.57, which is near median its 10-year median of 5.81 and 54.7% above the Biotechnology industry median of 3.60. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Quick Ratio is 5.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score
Get the complete analysis for OSTO:ISOFOL
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ISOFOL has been successfully added to your 
